SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma receives USFDA's nod for Ramipril Capsules

10 Jun 2011 Evaluate

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg. The product has a market size of approximately $95 million for the twelve months ending September 2010 according to IMS.

Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg is the generic equivalent to the reference listed drug Altace Capsules 1.25mg, 2.5mg, 5mg and 10mg of King Pharmaceuticals. Under the Cardiovascular (CVS) therapeutic segment Ramipril Capsules are indicated for the treatment of hypertension. Aurobindo now has a total of 138 ANDA approvals (108 Final approvals and 30 tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterological, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

Aurobindo Pharma Share Price

1488.50 9.95 (0.67%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×